Skip to main content
SpringerLink
Log in

Introduction: Abuse of Tobacco and Substances

  • Chapter
  • First Online:
Tobacco Cessation and Substance Abuse Treatment in Women’s Healthcare

  • 457 Accesses

Abstract

Substance abuse in pregnancy is known to have deleterious effects on neonates. These effects differ with respect to the substance ingested and can include neonatal abstinence syndrome, low birth weight, intrauterine fetal demise, and structural abnormalities such as gastroschisis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996-1998. Obstet Gynecol. 2003;101(2):374–9.

    PubMed  Google Scholar 

  2. Chasnoff IJ, McGourty RF, Bailey GW, Hutchins E, Lightfoot SO, Pawson LL, Fahey C, May B, Brodie P, McCulley L, Campbell J. The 4P’s Plus screen for substance use in pregnancy: clinical application and outcomes. J Perinatol. 2005;25(6):368–74.

    Article  PubMed  Google Scholar 

  3. Azadi A, Dildy III GA. Universal screening for substance abuse at the time of parturition. Am J Obstet Gynecol. 2008;198(5):e30–2. Epub 2008 Feb 14.

    Article  PubMed  Google Scholar 

  4. Substance Abuse and Mental Health Services Administration. Behavioral health barometer: United States, 2014. HHS publication no. SMA-15-4895. Rockville: Substance Abuse and Mental Health Services Administration; 2015. p. 14.

    Google Scholar 

  5. American College of Obstetricians and Gynecologists Committee Opinion Number 633: Alcohol abuse and other substance use disorders: ethical issues in obstetric and gynecologic patients; June 2015.

    Google Scholar 

  6. Ewing H. A practical guide to intervention in health and social services with pregnant and postpartum addicts and alcoholics: theoretical framework, brief screening tool, key interview questions, and strategies for referral to recovery resources. Martinez: The Born Free Project, Contra Costa County Department of Health Services; 1990.

    Google Scholar 

  7. Montgomery D, Plate C, Alder SC, Jones M, Jones J, Christensen RD. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium. J Perinatol. 2006;26(1):11–4.

    Article  CAS  PubMed  Google Scholar 

  8. Montgomery DP, Plate CA, Jones M, Jones J, Rios R, Lambert DK, Schumtz N, Wiedmeier SE, Burnett J, Ail S, Brandel D, Maichuck G, Durham CA, Henry E, Christensen RD. Using umbilical cord tissue to detect fetal exposure to illicit drugs: a multicentered study in Utah and New Jersey. J Perinatol. 2008;28(11):750–3. Epub 2008 Jul 3.

    Article  CAS  PubMed  Google Scholar 

  9. Stitely ML, Calhoun BC, Maxwell S, Nerhood R, Chaffin D. Prevalence of drug use in pregnant West Virginia patients. W V Med J. 2010;105:48–52.

    Google Scholar 

  10. Baxter FR, Nerhood R, Chaffin D. Characterization of babies discharged from Cabell Huntington Hospital during the calendar year 2005 with the diagnoses of neonatal abstinence syndrome. W V Med J. 2009;105(2):16–21.

    PubMed  Google Scholar 

  11. Hensel S, Seybold D, Lewis T, Burgess D, Casto A, Calhoun BC. Substance abuse in pregnancy: role of universal urine drug screening and addiction therapy in West Virginia. Poster presentation in 16th World Congress on Controversies in Obstetrics, Gynecology, and Infertility (COGI), Singapore, 19–22 July 2012.

    Google Scholar 

  12. Rementeria JL, Nunag NN. Narcotic withdrawal in pregnancy. Am J Obstet Gynecol. 1973;116:1152–6.

    CAS  PubMed  Google Scholar 

  13. Finnegan JP. Treatment issues for opioid dependent women during the perinatal period. J Psychoactive Drugs. 1991;23:191–202.

    Article  CAS  PubMed  Google Scholar 

  14. Jarvis MAE, Schnoll SH. Methadone maintenance and withdrawal in pregnant opioid addicts. In: Chiang CN, Finnegan LP, editors. Medication development for the treatment of pregnant addicts and their infants. Washington, DC: US Department of Health and Human Services; 1994. p. 58–77. NIDA Monograph 149.

    Google Scholar 

  15. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD. Opioid detoxification in pregnancy. Obstet Gynecol. 1998;92:854–8.

    CAS  PubMed  Google Scholar 

  16. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat. 2003;24:363–7.

    Article  PubMed  Google Scholar 

  17. Stewart RD, Nelson DB, Adhikari EH, McIntire DD, Roberts SW, Dashe JS, Sheffield JS. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol. 2013;209:267.e1–5.

    Article  Google Scholar 

  18. Hensel S, Seybold D, Lewis T, Burgess D, Casto A, Barnes A, Calhoun BC. Substance abuse in pregnancy: role of universal urine drug screening and outpatient addiction therapy in West Virginia. Poster presentation in 62nd annual meeting of Society for Reproductive Investigation (SGR), San Francisco, 26–28 March 2015.

    Google Scholar 

  19. Hoegerman G, Schnoll SH. Methadone maintenance and withdrawal in pregnant opioid addicts. Clin Perinatol. 1991;18:51–76.

    CAS  PubMed  Google Scholar 

  20. Briggs GG, Freeman RK, Yaffee SJ. Drugs in pregnancy and lactation. Baltimore: Williams and Wilkins; 1994. p. 557–8.

    Google Scholar 

  21. Cooper JR, Altman F, Brown BS, Czechowicz D, editors. Research on the treatment of narcotic addiction: state of the art. (NIDA Research Monograph 83-1201). Rockville: US Department of Health and Human Services; 1983.

    Google Scholar 

  22. Andres RL, Jones KL. Social and illicit drug use in pregnancy. In: Creasy RK, Resnick R, editors. Maternal-fetal medicine. Philadelphia: Saunders; 1994. p. 191–2.

    Google Scholar 

  23. Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction. 2008;103:1429–40.

    Article  PubMed  Google Scholar 

  24. Chutuape MA, Jasinski DR, Fingerhood MI, Stitzer ML. One, three, and six month outcomes following brief inpatient opioid detoxification. Am J Drug Alcohol Abuse. 2001;27:19–44.

    Article  CAS  PubMed  Google Scholar 

  25. Gossop M, Green L, Phillips G, Bradley B. Lapse, relapse, and survival among opiate addicts immediately after treatment: a prospective follow-up study. Br J Psychiatry. 1989;154:348–53.

    Article  CAS  PubMed  Google Scholar 

  26. Silsby H, Tennat FS. Short-term, ambulatory detoxification of opiate addicts using methadone. Int J Addict. 1974;9:167–70.

    Article  CAS  PubMed  Google Scholar 

  27. Jones HE, Johnson RE, Jasinski DR, O’Grady KE, Chisholm CA, Choo RE, Crocetti M, Dudas R, Harrow C, Huestis MA, Jansson LM, Lantz M, Lester BM, Milio L. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2004;79:1–10.

    Article  Google Scholar 

  28. Rothman KJ. Causes. Am J Epidemiol. 1976;104:587–92.

    CAS  PubMed  Google Scholar 

  29. Zierler S, Rothman KJ. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med. 1985;313:347–52.

    Article  CAS  PubMed  Google Scholar 

  30. Braken MB. Drug use in early pregnancy and congenital hear disease in offspring. N Engl J Med. 1986;314:1120.

    Google Scholar 

  31. Shaw GM, Malcoe LH, Swan SH, Cummins SK, Schulman J. Congenital cardiac anomalies and conditions during early pregnancy. Eur J Epidemiol. 1992;8:757–60.

    Article  CAS  PubMed  Google Scholar 

  32. Braken MB, Holford TR. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol. 1981;58:336–44.

    Google Scholar 

  33. Jick H, Holmes LB, Hunter JR, Madson S, Stergachis A. First-trimester drug use and congenital disorders. JAMA. 1981;246:343–6.

    Article  CAS  PubMed  Google Scholar 

  34. Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, et al. Maternal treatment with opioid analgesics and risk for birth defects. National Birth Defects Prevention Study. Am J Obstet Gynecol. 2011. doi:10.1016/j.ajog.2010.12.039.

    Google Scholar 

  35. Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction during pregnancy. In: SAHMSA/CSAT treatment improvement protocols. Rockville: Substance Abuse and Mental Health Services Administration; 2008. Available at www.ncbi.nlm.nih.gov/books/NBK26113.

  36. Substance Abuse and Mental Health Services Administration. Behavioral health barometer: United States, 2014. HHS publication no. SMA-15-4895. Rockville: Substance Abuse and Mental Health Services Administration; 2015. p. 19.

    Google Scholar 

  37. Substance Abuse and Mental Health Services Administration. Behavioral health barometer: United States, 2014. HHS publication no. SMA-15-4895. Rockville: Substance Abuse and Mental Health Services Administration; 2015. p. 17.

    Google Scholar 

  38. Substance Abuse and Mental Health Services Administration. Behavioral health barometer: United States, 2014. HHS publication no. SMA-15-4895. Rockville: Substance Abuse and Mental Health Services Administration; 2015. p. 4.

    Google Scholar 

  39. Tong VT, Jones JR, Dietz PM, D’Angelo D, Bombard JM. Trends in smoking before, during, and after pregnancy—Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 31 sites, 2000-2005. MMWR Surveill Summ. 2009;58:1–31.

    Google Scholar 

  40. Jaddoe VWV, Verburg BO, de Ridder MAJ, Hofman A, Mackenbach JP, Moll HA, Steegers EAP, Witteman JCM, et al. Maternal smoking and fetal growth characteristics in different periods of pregnancy. The generation R study. Am J Epidemiol. 2007;165:1207–15.

    Article  PubMed  Google Scholar 

  41. Ingvarsson RF, Bjarnason AO, Dagbjartsson A, Hardardottir H, Haraldsson A, Thorkelsson T, et al. The effects of smoking in pregnancy on factors influencing fetal growth. Acta Paediatr. 2007;96:383–6.

    Article  PubMed  Google Scholar 

  42. Okah FA, Hoff GL, Dew P, Cai J, et al. Cumulative and residual risks of small for gestational age neonates after changing pregnancy-smoking behaviors. Am J Perinatol. 2007;24:191–6.

    Article  PubMed  Google Scholar 

  43. Villalbi JR, Salvador J, Cano-Serral G, Rodriguez-Sanz MC, Borrell C. Maternal smoking, social class and outcomes of pregnancy. Paediatr Perinat Epidemiol. 2007;21:441–7.

    Article  PubMed  Google Scholar 

  44. Burns L, Mattick RP, Wallace C. Smoking patterns and outcomes in a population of pregnant women and other substance use disorders. Nicotine Tob Res. 2008;10:969–74.

    Article  PubMed  Google Scholar 

  45. McCowan LM, Dekker GA, Chan EL, Stewart A, et al. Spontaneous preterm birth and small for gestational age infants in women who stop smoking early in pregnancy: prospective cohort study. BMJ. 2009;338:b1081.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Uncu Y, Ozcakir A, Ecran I, Bilgel N, Uncu G. Pregnant women quit smoking: what about fathers? Survey study in Bursa Region, Turkey. Croat Med J. 2005;46:832–7.

    PubMed  Google Scholar 

  47. Salihu HM, Aliyu MH, Pierre-Louis BJ, Alexander GR. Levels of excess infant deaths attributable to maternal smoking during pregnancy in the United States. Matern Child Health J. 2003;7:219–27.

    Article  PubMed  Google Scholar 

  48. Jensen MS, Toft G, Thulstrup AM, Bonde JP, Olsen J, et al. Cryptorchidism according to maternal gestational smoking. Epidemiology. 2007;18(2):220–5.

    Article  PubMed  Google Scholar 

  49. Honein MA, Rasmussen SA, Reefhuis J, Romitti PA, Lammer EJ, Sun L, Correa A, et al. Maternal smoking and environmental tobacco smoke exposure and the risk of orofacial clefts. Epidemiology. 2007;18(2):226–33.

    Article  PubMed  Google Scholar 

  50. Schmid JM, Kuehni CE, Strippoli MPF, Roiha HL, Pavlovic R, Latzin P, Gallati S, Kraemer R, Dahinden C, Frey U, on behalf of the Swiss Pediatric Respiratory Research Group, et al. Maternal tobacco smoking and decreased leukocytes, including dendritic cells, in neonates. Pediatr Res. 2007;61(4):462–6.

    Article  Google Scholar 

  51. Goksor EA, et al. The impact of pre- and post-natal smoke exposure on future asthma and bronchial hyper-responsiveness. Acta Paediatr. 2007;96:1030–5.

    Article  PubMed  Google Scholar 

  52. Noakes PS, Thomas R, Lane C, Mori TA, Barden AE, Devadason SG, Prescott SL, et al. Association of maternal smoking with increased infant oxidative stress at 3 months of age. Thorax. 2007;62:714–7.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Ananth CV, Cnattingius S, et al. Influence of maternal smoking on placental abruption in successive pregnancies: a population-based prospective cohort study in Sweden. Am J Epidemiol. 2007;166:289–95.

    Article  PubMed  Google Scholar 

  54. Hogberg L, Cnattingius S, et al. The influence of maternal smoking habits on the risk of subsequent stillbirth: is there a causal relation? BJOG. 2007;114:699–704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Meeker JD, Missmer SA, Vitonis AF, Cramer DW, Hauser R, et al. Risk of spontaneous abortion in women with childhood exposure to parental cigarette smoke. Am J Epidemiol. 2007;166:571–5.

    Article  PubMed  Google Scholar 

  56. Goodwin RD, Keyes K, Simuro N, et al. Mental disorders and nicotine dependence among pregnant women in the United States. Obstet Gynecol. 2007;109:875–83.

    Article  PubMed  Google Scholar 

  57. Indredavik MS, Brubakk A, Romundstad P, Vik T, et al. Prenatal smoking exposure and psychiatric symptoms in adolescence. Acta Paediatr. 2007;96:377–82.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Nigg JT, Breslau N, et al. Prenatal smoking exposure, low birth weight, and disruptive behavior disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(3):362–9.

    Article  PubMed  Google Scholar 

  59. Roza SJ, Verburg BO, Jaddoe VWV, Hofman A, Mackenbach JP, Steegers EAP, Witteman JCM, Verhulst FC, Tiemeier H, et al. Effects of maternal smoking in pregnancy on prenatal brain development. The General R Study. Eur J Neurosci. 2007;25:611–7.

    Article  PubMed  Google Scholar 

  60. Lambe M, Hultman C, Torrang A, Maccabe J, Cnattingius S. Maternal smoking during pregnancy and school performance at age 16. Epidemiology. 2006;17:524–30.

    Article  PubMed  Google Scholar 

  61. Lumley J, Oliver SS, Chamberlain C, Oakley L. Interventions for promoting smoking cessation during pregnancy (Review). The Cochrane Collaboration. 2008(1).

    Google Scholar 

  62. Mainous AG, Hueston WJ. The effect of smoking cessation during pregnancy on preterm delivery and low birthweight. J Fam Pract. 1994;38:262–6.

    PubMed  Google Scholar 

  63. Bernstein IM, Mongeon JA, Badger GJ, Solomon L, Heil SH, Higgins ST. Maternal smoking and its association with birth weight. Obstet Gynecol. 2005;106:986–91.

    Article  PubMed  Google Scholar 

  64. Horta BL, Victora CG, Menezes AM, Halpern R, Barros FC. Low birthweight, preterm births and intrauterine growth retardation in relation to maternal smoking. Paediatr Perinat Epidemiol. 1997;11:140–51.

    Article  CAS  PubMed  Google Scholar 

  65. Gnann H, Engelman C, Skopp G, Winkler M, Auwarter V, Dresen S, et al. Identification of 48 homologues of phosphatidylethanol in blood by LC-ESI-MS/MS. Anal Bioanal Chem. 2010;396:2415–23.

    Article  CAS  PubMed  Google Scholar 

  66. Gunnarson T, Karlsson A, Hansson P, Johnson G, Alling C, Odham G. Determination of phosphatidylethanol in blood from alcoholic males using high-performance liquid chromatography and evaporative light scattering or electrospray mass spectrometric detection. J Chromatogr B Biomed Sci Appl. 1998;705:243–9.

    Article  Google Scholar 

  67. Helander A, Zheng Y. Molecular species of the alcohol biomarker phosphatidylethanol in human blood measured by LC-MS. Clin Chem. 2009;55:1395–405.

    Article  CAS  PubMed  Google Scholar 

  68. Kwak HS, Han JY, Ahn HK, Kim MH, Ryu HM, Kim MY, et al. Blood levels of phosphatidylethanol in pregnant women reporting positive alcohol ingestion, measured by an improved LC-MS/MS analytical method. Clin Toxicol. 2012;50:886–91.

    Article  CAS  Google Scholar 

  69. Kwak HS, Han JY, Choi JS, Ahn HK, Ryu HM, Chung HJ, Cho DH, Shin CY, Velazqueza-Armenta EY, Nava-Ocampo AA. Characterization of phosphatidylethanol blood concentrations for screening alcohol consumption in early pregnancy. Clin Toxicol. 2014;52:25–31.

    Article  CAS  Google Scholar 

  70. Varga A, Hansson P, Johnson G, Alling C. Normalization rate and cellular localization of phosphatidylethanol in whole blood from chronic alcoholics. Clin Chim Acta. 2000;299:141–50.

    Article  CAS  PubMed  Google Scholar 

  71. Gnann H, Weinmann W, Thierauf A. Formation of phosphatidylethanol and its subsequent elimination during an extensive drinking experiment over 5 days. Alcohol Clin Exp Res. 2012;36:1507–11.

    Article  CAS  PubMed  Google Scholar 

  72. Yamamoto Y, Yamamoto K, Fukui Y, Kurishita A. Teratogenic effects of metamphetamine in mice. Nihon Hoigaku Zasshi. 1992;46:126–31.

    CAS  PubMed  Google Scholar 

  73. Colado ML, O’Shea E, Granados R, Misra A, Murray TK, et al. A study of the neurotoxic effect of MDMA (‘ecstasy’) on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol. 1997;121:827–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. He N, Lidow MS. Cerebral cortical abnormalities seen in non-human primate model of prenatal cocaine exposure are not related to vasoconstriction. Neurotoxicology. 2004;25:419–32.

    Article  CAS  PubMed  Google Scholar 

  75. Plessinger MA. Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. Obstet Gynecol Clin North Am. 1998;25:119–38.

    Article  CAS  PubMed  Google Scholar 

  76. Nora JJ, Vargo TA, Nora AH, Love KE, McNamara DG. Dexamphetamine: a possible environmental trigger in cardiovascular malformations. Lancet. 1970;1:1290–1.

    Article  CAS  PubMed  Google Scholar 

  77. Bays J. Fetal vascular disruption with prenatal exposure to cocaine or metamphetamine. Pediatrics. 1994;87:416–8.

    Google Scholar 

  78. Lipshultz SE, Frassiac JJ, Orav EJ. Cardiovascular abnormalities in infants prenatally exposed to cocaine. J Pediatr. 1991;118:44–51.

    Article  CAS  PubMed  Google Scholar 

  79. Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine dependence and abuse. Cochrane Database Syst Rev. 2001,(4):CD003022.

    Google Scholar 

  80. Trezza V, Campolongo P, Cassano T, et al. Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal behavioral study in Wistar rats. Psychopharmacology (Berl). 2008;198(4):529–37.

    Article  CAS  Google Scholar 

  81. Fried PA, Makin JE. Neonatal behavioral correlates of prenatal exposure to marijuana, cigarettes, and alcohol in a low risk population. Neurotoxicol Teratol. 1987;9:1–7.

    Article  CAS  PubMed  Google Scholar 

  82. de Moraes Barros MC, Guinsburg R, de Araujo Peres C, Mitsuhiro S, Chalem E, Laranjeira RR. Neurobehavioral profile of healthy full-term newborn infants of adolescent mothers. Early Hum Dev. 2008;84:281–7.

    Article  PubMed  Google Scholar 

  83. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol. 2000;22(3):325–36.

    Article  CAS  PubMed  Google Scholar 

  84. Richardson GA, Ryan C, Willford J, Day NL, Goldschmidt L. Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. Neurotoxicol Teratol. 2002;4(3):309–20.

    Article  Google Scholar 

  85. Schempf AH, Strobino DM. Illicit drug use and adverse birth outcomes: is it drugs or context? J Urban Health. 2008;85(6):858–73.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Webster WS, Brown-Woodman PD. Cocaine as a cause for congenital malformations of vascular origin: experimental evidence in the rat. Teratology. 1990;41:689–97.

    Article  CAS  PubMed  Google Scholar 

  87. Frank DA, Augustyn M, Knight WG, et al. Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. JAMA. 2001;285:1613.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: mental health findings. 2012.

    Google Scholar 

  89. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8–19. doi:10.1001/archpsyc.51.1.8.

    Article  CAS  PubMed  Google Scholar 

  90. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264(19):2511–8. doi:10.1001/jama.264.19.2511.

    Article  CAS  PubMed  Google Scholar 

  91. Drake RE, Wallach MA. Moderate drinking among people with severe mental illness. Hosp Community Psychiatry. 1993;44(8):780–2.

    CAS  PubMed  Google Scholar 

  92. Dutra L, Statthopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165:179–87.

    Article  PubMed  Google Scholar 

  93. Moran P, Madgula RM, Gilvarry E, Findlay M. Substance misuse during pregnancy: its effects and treatment. Fetal Maternal Med Rev. 2009;20:1–16.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, West Virginia University-Charleston, Charleston, WV, USA

    Byron C. Calhoun MD, FACOG, FACS, FASAM, MBA

Authors
  1. Byron C. Calhoun MD, FACOG, FACS, FASAM, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Byron C. Calhoun MD, FACOG, FACS, FASAM, MBA .

Editor information

Editors and Affiliations

  1. West Virginia University-Charleston, Charleston, USA

    Byron C. Calhoun

  2. Women&Chldrn’sDvsnCharlestonAreaMedCentr, Family Resource Center, Charleston, West Virginia, USA

    Tammi Lewis

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Calhoun, B.C. (2016). Introduction: Abuse of Tobacco and Substances. In: Calhoun, B., Lewis, T. (eds) Tobacco Cessation and Substance Abuse Treatment in Women’s Healthcare. Springer, Cham. https://doi.org/10.1007/978-3-319-26710-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26710-4_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26708-1

  • Online ISBN: 978-3-319-26710-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation